Salestools LogoSalestools
Salestools LogoSalestools
Biotech

AbCellera

AbCellera raises $555M Series B at $5.7B valuation

$555M
Total Raised
Series B
Latest Round
2012
Founded
400+
Employees
2389 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada
1 min read

Quick Facts

Valuation
$5.7B
Latest Round Size
$555M
Latest Round Date
June 2024

AbCellera: Series B Funding Round

AbCellera has successfully raised $555M in Series B funding, reaching a valuation of $5.7B.

Company Overview

Antibody discovery platform

Funding Details

The Series B round was led by Peter Thiel, with participation from Eli Lilly, Fast Forward Innovations, DCVC Bio.

Company Information

  • Headquarters: 2389 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada
  • Founded: 2012
  • Employees: 400+
  • Category: Biotech

Investment

AbCellera plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

  • Peter Thiel: Verified investor in Series B
  • Eli Lilly: Verified investor in Series B
  • Fast Forward Innovations: Verified investor in Series B
  • DCVC Bio: Verified investor in Series B

Key Investors

Peter Thiel
Lead Investor
Verified investor in Series B
Eli Lilly
Investor
Verified investor in Series B
Fast Forward Innovations
Investor
Verified investor in Series B
DCVC Bio
Investor
Verified investor in Series B

Topics

verified(3079)real-funding(3079)series-b(280)abcellerabiotech2389-health-sciences-mall

About the Author

Editorial Team
Editorial Team
Curated funding news from verified sources

Related Company Reports

Biotech
Orna Therapeutics

Orna Therapeutics Raises $251M Series B

Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases

Emma Rodriguez
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics

Forge Biologics Raises $120M Series C

Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology

Vir Biotechnology Raises $250M

Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$250M